Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Tragic Death Highlights Perils Of Binge Drinking, UK
Commenting on the tragic death of 22-year-old Gary Reinbach, who died as a result of binge drinking since the age of 13, Dr Peter Carter, Chief Executive of the Royal College of Nursing (RCN), said:

Positive CHMP Opinion For JAVLOR(R) In Metastatic Treatment Of Bladder Cancer After Failure Of A Prior Platinum-Containing Regimen
Laboratoires Pierre Fabre announce that the Committee for Medicinal Products for Human Use (CHMP), the scientific advisory committee of the European Medicines Agency (EMEA), has issued a positive opinion supporting approval and is recommending to grant marketing authorisation for JAVLOR(R) as monotherapy in metastatic treatment of bladder cancer (advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen).
News of the day
UC Irvine To Fire Nurse Who Questioned Unsafe Patient Care Practices
Registered nurses and hospital employees will hold a patient care vigil Tuesday night, at UC Irvine Medical Center (UCIMC), to protest the administration"s retaliatory actions against Ethel Mark, an RN who has worked in the hospital"s cardiac care unit for the last seven years as a model patient advocate. Ms. Mark was informed that she could expect to be terminated by the beginning of July.
Public Health

InSite Vision Announces FDA Approval Of New Ophthalmic Product Enabled By InSite's DuraSite® Technology

InSite Vision Incorporated (OTCBB:INSV) announced that Bausch & Lomb has received approval of Besivance™ (besifloxacin ophthalmic suspension) 0.6% for the treatment of bacterial conjunctivitis ("pink eye") in patients one year and older from the U.S. Food and Drug Administration (FDA). Besivance™ is formulated with InSite Vision"s DuraSite® technology, a synthetic polymer delivery vehicle that enhances the retention time of the drug on the surface of the eye. Bausch & Lomb licensed the besifloxacin DuraSite formulation from InSite Vision in 2003 following Phase 1 clinical studies and continued development of this broad-spectrum, anti-infective drop specifically for ophthalmic use. Based on the terms of the agreement, InSite will receive competitive single-digit royalties on global net sales of the product. Besivance is being launched in the U.S. in the second quarter of 2009. The product will be promoted by the sales forces of both Bausch & Lomb and Pfizer, Inc. under a co-promotion agreement involving both companies" prescription ophthalmic pharmaceuticals. "We expect this product to offer patients a valuable therapeutic option for one of the most common ocular conditions worldwide," said Louis Drapeau, InSite"s Chief Executive Officer. "The launch of Besivance represents the second commercially available product incorporating InSite"s DuraSite platform, in addition to AzaSite. This is an exciting milestone which further demonstrates the clinical value of the technology. We continue to look for new opportunities to utilize DuraSite to develop valuable products that treat unmet eye care needs." DuraSite is a synthetic polymer of cross-linked polyacrylic acid that stabilizes small molecules in an aqueous matrix, allowing for targeted and sustained administration. By increasing the time that a therapeutic level of medication remains on the eye"s surface, DuraSite enables a less frequent dosing schedule, increases patient compliance, and increases the therapeutic efficacy. InSite Vision


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009